-
(单词翻译:双击或拖选)
Frozen cells reveal a clue for a vaccine1 to block the deadly TB bug2
Tuberculosis4 may seem like a relic5 of the past in wealthy countries, yet it still kills more people worldwide than any other infectious disease besides COVID – with about 1.6 million people dying from TB annually6. And the one approved vaccine – invented more than a century ago – is only reliably protective when given to children.
Now, scientists at South Africa's University of Cape7 Town have taken a major step toward creating an mRNA vaccine against TB that could work for people of all ages. The key to their breakthrough: An unusual set of blood samples that were kept in deep freeze for nearly two decades – until the vital information they contained could finally be unlocked thanks to some new technology.
To explain, one of the researchers behind the effort, Munyaradzi Musvosvi, ushers8 me into a room with several enormous metal vats9. "These are our cryotanks," he says. "The cells are kept here in liquid nitrogen." He pulls the lid off one of the tanks and plumes10 of white vapor11 spill out. "It's kind of hazy," he says, pointing deep inside. "But you just might be able to see a little box there."
Blood samples from high school students
The samples were collected from about 6,000 South African high school students beginning in 2005. And they were originally intended – and used – for a range of other research on TB. But Musvosvi says the researchers soon realized that the cells contained some rare clues for how the human immune system can kill the bacterium12.
That's because follow-up samples had been taken repeatedly over a two year period – and because of one of the particularities of TB: The bacterium that causes it is so widespread that more than 80 percent of South Africans have been exposed to it; Yet only about one in ten of those people actually develop the disease – often months or even years after exposure.
This meant that when the researchers analyzed13 the first round of blood samples they could identify a subset who had immune cells indicating that they had been exposed to TB but had not gotten sick. Then, says Musvosvi, "as we follow them up, we could document that some of these adolescents were [subsequently] diagnosed with active TB disease. They had symptoms and we could actually measure the bacteria in the sputum that they were coughing up."
In other words, says Musvosvi, the researchers could set up a comparison. "It allowed us to ask the question: Of those adolescents who progressed to disease during this two-year period, what was different between them and those who managed to control infection during the two year follow-up?"
Specifically, he and his collaborators wondered: Did the exposed students who never got sick have a different set of immune cells. And, if so, were those immune cells – they're called T-cells – latching15 on to different, presumably more vulnerable, parts of the TB bacteria? As Musvosvi puts it, "Out of all the proteins that TB makes, what do these T-cells recognize?"
Except there was a snag. Scientists didn't actually have a good way of doing that kind of analysis of T-cells. At least not one that wasn't prohibitively expensive.
And so the cells were left sitting in the cryotanks for more than a decade. "Yeah," says Musvosvi, with a wry16 smile. "They were kept nicely frozen for quite a long time."
A breakthrough in 2019
Then in 2019, a researcher at Stanford named Huang Huang came up with a new – and far more affordable17 – method to determine what proteins a given T-cell is reacting to.
Huang, now with the pharmaceutical18 company Gilead Sciences, says the moment he realized the technique was going to work was somewhat eerie19. "It was about four in the morning. The lab was empty. No persons around – only myself," he says. "Then I see the machine give this positive result, and it was very, very exciting for me. Because this had not been done previously20."
But Huang says he didn't appreciate just how useful the technique – and several related ones developed with collaborators – might prove until the researchers in South Africa found out about the work and proposed teaming up.
Huang's reaction: "This is a great opportunity to explore these very precious samples."
So they thawed21 them out and got to work.
This year the team was able to publish their findings in the journal Nature Medicine. Just as they'd hoped, they discovered several T-cells that were far more common to people who are able to control TB. And they've been able to determine several TB proteins that these T-cells focus on.
Back in his office, Musvosvi pulls them up on his computer. "So here you can see that so far we've identified three proteins."
This would have been helpful information under any circumstances, he says. The research group he's part of is called the South African Tuberculosis Vaccine Initiative, "and what we're trying to do here is to identify priority targets that vaccine developers could then use to develop a TB vaccine that is more efficacious."
But it's particularly handy in light of the final twist to this tale: The recent development of a whole new class of vaccines22 — the highly effective "mRNA" shots like those made against COVID by Pfizer and Moderna.
With traditional vaccines, notes Musvosvi, even if you know what proteins on a virus or bacterium a person's immune system can latch14 on to to kill it, you still have to find a way to manufacture and then insert those proteins into the body as part of the vaccine – so that the body can prepare defenses against them.
By contrast, mRNA vaccines are more like a plug and play system: You just insert the genetic23 code for the proteins into the vaccine, and the body uses that code to make them. Or as Musvosvi puts it, "the body does [the manufacturing] for you." This, in turn, means that "in terms of scaling up, it's quite easy."
Indeed, several vaccine developers are already working on prototype mRNA vaccines against TB based on the proteins identified by Musvosvi and his collaborators, in order to check if they work in animals. These include both for-profit companies like Pfizer as well as a separate team in South Africa that's part of an mRNA research and manufacturing "hub" launched by the World Health Organization and other partners.
If any of those prototypes prove successful, it will likely still take several more years before a version for humans is finalized24.
But Musvosvi says he's optimistic that after decades of failed efforts to make a better TB vaccine, scientists may finally have hit on a winning approach. And given how many people suffer from TB he adds, "It would be a game changer."
收听单词发音 |
1
vaccine
|
|
| n.牛痘苗，疫苗；adj.牛痘的，疫苗的 | |
参考例句： |
|
|
|
|
2
bug
|
|
| n.虫子；故障；窃听器；vt.纠缠；装窃听器 | |
参考例句： |
|
|
|
|
3
transcript
|
|
| n.抄本，誊本，副本，肄业证书 | |
参考例句： |
|
|
|
|
4
tuberculosis
|
|
| n.结核病，肺结核 | |
参考例句： |
|
|
|
|
5
relic
|
|
| n.神圣的遗物，遗迹，纪念物 | |
参考例句： |
|
|
|
|
6
annually
|
|
| adv.一年一次，每年 | |
参考例句： |
|
|
|
|
7
cape
|
|
| n.海角，岬；披肩，短披风 | |
参考例句： |
|
|
|
|
8
ushers
|
|
| n.引座员( usher的名词复数 )；招待员；门房；助理教员v.引，领，陪同( usher的第三人称单数 ) | |
参考例句： |
|
|
|
|
9
vats
|
|
| varieties 变化，多样性，种类 | |
参考例句： |
|
|
|
|
10
plumes
|
|
| 羽毛( plume的名词复数 )； 羽毛饰； 羽毛状物； 升上空中的羽状物 | |
参考例句： |
|
|
|
|
11
vapor
|
|
| n.蒸汽，雾气 | |
参考例句： |
|
|
|
|
12
bacterium
|
|
| n.(pl.)bacteria 细菌 | |
参考例句： |
|
|
|
|
13
analyzed
|
|
| v.分析( analyze的过去式和过去分词 )；分解；解释；对…进行心理分析 | |
参考例句： |
|
|
|
|
14
latch
|
|
| n.门闩，窗闩；弹簧锁 | |
参考例句： |
|
|
|
|
15
latching
|
|
| n.闭塞；闭锁；关闭；闭塞装置v.理解( latch的现在分词 )；纠缠；用碰锁锁上（门等）；附着（在某物上） | |
参考例句： |
|
|
|
|
16
wry
|
|
| adj.讽刺的；扭曲的 | |
参考例句： |
|
|
|
|
17
affordable
|
|
| adj.支付得起的，不太昂贵的 | |
参考例句： |
|
|
|
|
18
pharmaceutical
|
|
| adj.药学的，药物的；药用的，药剂师的 | |
参考例句： |
|
|
|
|
19
eerie
|
|
| adj.怪诞的；奇异的；可怕的；胆怯的 | |
参考例句： |
|
|
|
|
20
previously
|
|
| adv.以前，先前（地） | |
参考例句： |
|
|
|
|
21
thawed
|
|
| 解冻 | |
参考例句： |
|
|
|
|
22
vaccines
|
|
| 疫苗，痘苗( vaccine的名词复数 ) | |
参考例句： |
|
|
|
|
23
genetic
|
|
| adj.遗传的，遗传学的 | |
参考例句： |
|
|
|
|
24
finalized
|
|
| vt.完成（finalize的过去式与过去分词形式） | |
参考例句： |
|
|
|
购买
在百度中搜索